Brought to you by 
REGENXBIO gets IP from UPenn, U. of Minnesota
09 Apr 2015
Executive Summary
REGENXBIO Inc. licensed exclusive rights to intellectual property from the University of Pennsylvania and University of Minnesota surrounding the delivery of AAV vectors for the treatment of MPS I (Hurler syndrome) and MPS II (Hunter syndrome).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
REGENXBIO gets IP from UPenn, U. of Minnesota
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice